About: Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 January 2005

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique (publié 2005) (fr) 2005 թվականին հրատարակված գիտական հոդված (hy) наукова стаття, опублікована в січні 2005 (uk) artículu científicu espublizáu en xineru de 2005 (ast) artikull shkencor i botuar më 01 janar 2005 (sq) scientific article published on 01 January 2005 (en)
publication date	wds:Q80969122-521B4F7E-6E78-400E-96D1-AAEA143A7E0D
publication date	2005-01-01 00:00:00Z (xsd:dateTime)
exact match	wds:Q80969122-24FCC752-F71D-4695-B3FA-577FEB8E5AA3
exact match	https://scigraph.springernature.com/pub.10.1023/b:drug.0000047103.64335.b0
cites work	wds:Q80969122-01AE86AB-E160-49A3-9BB8-B0749A7963EF wds:Q80969122-0BE9B6DB-D145-4426-ADA4-83CFB890F0A5 wds:Q80969122-19FE2B0D-FFCD-47DE-88A5-8A4500BC817C wds:Q80969122-2E35F9EE-19CE-4595-B389-94C3F396D5D4 wds:Q80969122-348938E2-AF28-41F6-A268-3DB615D8FC83 wds:Q80969122-4115B83D-38AB-4195-BA7D-839E98FA98CA wds:Q80969122-6E4BCA18-459A-4553-A780-AF3673EC3BBD wds:Q80969122-716C4666-0718-41A0-99D0-142AF3E96911 wds:Q80969122-7B6E3919-41CC-4E8A-8B45-F5DBDD7E0E45 wds:Q80969122-83F69EAA-1CBA-4970-9EF7-F49FEE0A1518 wds:Q80969122-8B32CA28-9EEA-4AB3-AE5C-B18BCC5CC6F3 wds:Q80969122-8D98ED58-8B9C-402E-BA9D-0ECA72195D31 wds:Q80969122-8ED33863-D228-4231-89AF-57A08B517106 wds:Q80969122-9174DA62-6878-4DD6-92A5-D875492FB5BC wds:Q80969122-96C55DCE-0424-46DE-B378-674670EF7AE3 wds:Q80969122-9A2C711B-5A40-4269-BA68-7C3AFA3BAA81 wds:Q80969122-A3723882-F7BC-43CF-AC5C-7E0163ACB244 wds:Q80969122-BC898508-D211-4AAF-9E71-10172202FB1E wds:Q80969122-BF4C5D33-D16C-4360-8865-3902954EB237 wds:Q80969122-BF830396-A168-4471-8C21-7199B03616EE wds:Q80969122-C3DF2F18-A4C2-41AA-AC0B-015BD1E34465 wds:Q80969122-C7ECB336-F5BF-48FE-9AD1-9531A27936BE wds:Q80969122-D3E48763-C8EB-43A6-BA2E-B98E589EBEBD wds:Q80969122-D7EDA726-E98C-4BEC-B8AF-56DEC5997D22 wds:Q80969122-E9D4E720-1D0E-478F-8079-7862FDE34D6C wds:Q80969122-FCEC3D9B-3415-48C7-B9B1-1FBDDF551950
cites work	K-252a inhibits nerve growth factor-induced trk proto-oncogene tyrosine phosphorylation and kinase activity Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences Mutational analysis of the TrkA gene in prostate cancer. Intracellular signaling pathways activated by neurotrophic factors High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Neurotrophin stimulation of human melanoma cell invasion: selected enhancement of heparanase activity and heparanase degradation of specific heparan sulfate subpopulations. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587) Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555) Immunohistochemical analysis of TrkA neurotrophin receptor expression in human non-neuronal carcinomas Inhibition of the cellular actions of nerve growth factor by staurosporine and K252A results from the attenuation of the activity of the trk tyrosine kinase Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells Expression of a Trk high affinity nerve growth factor receptor in the human prostate Molecular characterization of neurotrophin expression and the corresponding tropomyosin receptor kinases (trks) in epithelial and stromal cells of the human prostate Nerve growth factor stimulates clonal growth of human lung cancer cell lines and a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine kinase signaling Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts Identification of the neurotrophin receptors p75 and trk in a series of Wilms' tumors CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity Role of nerve growth factor-like protein in the paracrine regulation of prostate growth Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein. Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a, and its mechanism of action Prodrug esters of the indolocarbazole CEP-751 (KT-6587) The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma
author name string	wds:Q80969122-04D1E782-7D8B-4403-9142-5564AB6B2204 wds:Q80969122-0B43F932-24BA-4E23-B8FD-C327FD12A0F3 wds:Q80969122-1BE50C2C-8833-4C58-AECD-670D5C4F97BD wds:Q80969122-30D159E3-D6B7-435D-B82A-C336C5BB1C01 wds:Q80969122-464B7516-7F40-4E95-B656-4436D4FD90B5 wds:Q80969122-5A61D480-48A7-49BD-AC22-BD46EFAD073D wds:Q80969122-5ED8C881-D854-4260-90B1-B9692A2C5EAA wds:Q80969122-777592BB-2F70-469B-A700-53576A732004 wds:Q80969122-8A4B3E20-E868-42D6-91B8-A00719624172 wds:Q80969122-96F97CD1-CCD6-4B51-B55D-F4D1EF18D5E1 wds:Q80969122-D496FE12-2E49-441A-A2D2-8E1D14A86081
author name string	Nicholas J Vogelzang Pankaj Bhargava Philmore Robertson John L Marshall Hedy Kindler John Deeken Naiyer Rizvi Michael J Hawkins Margaret Dordal Stacy Boylan Taina Luhtala
rdfs:label	Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor (en) Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor (nl) Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor (sq)
skos:prefLabel	Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor (en) Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor (nl) Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor (sq)
name	Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor (en) Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor (nl) Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor (sq)
author	wds:Q80969122-3EFCDC9A-CE9F-4CED-A930-0C4D280DBB37
author	Mark J Ratain
title	wds:Q80969122-B78EFB35-477F-45D3-909F-7799AAA69338
title	Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor (en)
page(s)	wds:Q80969122-0E8034E3-8386-4BB5-AC36-F3AB73CA8BD5

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software